- Phototherapeutic Keratectomy
- Amniotic Membrane Transplants
- Anterior Stromal Puncture
- Conjunctival Flaps
Corneal Endothelial Dystrophy Market was valued at USD 168 billion in 2022 and is poised to grow at a CAGR of 7.5% over 2023-2029. Corneal endothelial dystrophy is a group of rare hereditary disorders characterized by bilateral abnormal deposition of substances in the cornea. Based on the diagnosis type, the cornea examination and grading segment is anticipated to dominate the corneal endothelial dystrophy market share over the forecast period. According to the American Academy of Ophthalmology, congenital corneal opacities have a prevalence of 6:1,00,000 in newborns and 3:1,00,000 excluding congenital glaucoma patients. With an increasingly aging population, awareness of the disorder is also increasing, driving the corneal endothelial dystrophy market growth. However, the side effects associated with the treatment procedures might hinder the market growth. Initiatives by the government and increasing reimbursement policies are opportunities for the growth of the market.
Fastest Growing Market
There has been an increase in technologies involved in the diagnosis and treatment of the disease with an increased clinical trial in the eye disease segment owing to the growing healthcare expenditures. For Instance, Rhopressa (Netarsudil ophthalmic solution), developed by Aerie Pharmaceuticals is used in the treatment of Fuchs endothelial corneal dystrophy. Thus, the increased awareness, research, and development for rare disorders will lead to the growth of the market within the forecast period. Whereas the high cost of treatment could pose as a restraining factor for the market growth.
The corneal endothelial dystrophy market was valued at USD 168 billion in 2022 and is expected to grow at a 7.5% CAGR over the forecast period 2023 – 2029.
Initiatives by the government and increasing reimbursement policies are key opportunities for the corneal endothelial dystrophy market.
An increasing aging population and a rise in awareness of the disorder are the growth drivers in the corneal endothelial dystrophy market.
Kowa Company, Ltd., Trefoil Therapeutics, Alcon, Price Vision Group, ProQR Therapeutics, Emmecell, Pfizer Inc., GlaxoSmithKline plc., Bausch Health Companies Inc., Bayer AG, Allergan, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., and Novartis AG are a few companies operating in the Corneal Endothelial Dystrophy market.